GIIDGeneral Instrument Interface Document
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
After completion GIID will be owned 40% by Glanbia and 60% by the Society and will be known as Glanbia Ireland.
U: a=homme oled giid nigu tead viis kopikat, voi senti meil on nuud sendid jah 'but tomorrow you'll be a guide like five kopecks or cents, we have cents now yes'
Immunic announced that the company will present previously unpublished data regarding the company's program, IMU-838, at the GI Inflammatory Diseases Summit, or GIIDS. IMU-838, currently in phase 2 clinical development for the treatment of ulcerative colitis (UC) and relapsing-remitting multiple sclerosis, or RRMS, is an orally available, next-generation selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme dihydroorotate dehydrogenase, or DHODH.